Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ITGB1BP1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ITGB1BP1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ITGB1BP1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ITGB1BP1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ITGB1BP1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:009013224 | Skin | AK | epithelium migration | 70/1910 | 360/18723 | 8.28e-08 | 3.89e-06 | 70 |
GO:199077820 | Skin | AK | protein localization to cell periphery | 66/1910 | 333/18723 | 9.18e-08 | 4.21e-06 | 66 |
GO:009013024 | Skin | AK | tissue migration | 70/1910 | 365/18723 | 1.45e-07 | 6.29e-06 | 70 |
GO:000166726 | Skin | AK | ameboidal-type cell migration | 85/1910 | 475/18723 | 1.72e-07 | 7.24e-06 | 85 |
GO:003238619 | Skin | AK | regulation of intracellular transport | 65/1910 | 337/18723 | 3.23e-07 | 1.27e-05 | 65 |
GO:003295628 | Skin | AK | regulation of actin cytoskeleton organization | 66/1910 | 358/18723 | 1.40e-06 | 4.26e-05 | 66 |
GO:01501179 | Skin | AK | positive regulation of cell-substrate junction organization | 14/1910 | 33/18723 | 1.58e-06 | 4.73e-05 | 14 |
GO:190495126 | Skin | AK | positive regulation of establishment of protein localization | 60/1910 | 319/18723 | 2.14e-06 | 6.12e-05 | 60 |
GO:003315723 | Skin | AK | regulation of intracellular protein transport | 47/1910 | 229/18723 | 2.31e-06 | 6.52e-05 | 47 |
GO:005101728 | Skin | AK | actin filament bundle assembly | 36/1910 | 157/18723 | 2.48e-06 | 6.76e-05 | 36 |
GO:001063220 | Skin | AK | regulation of epithelial cell migration | 56/1910 | 292/18723 | 2.49e-06 | 6.76e-05 | 56 |
GO:190188815 | Skin | AK | regulation of cell junction assembly | 43/1910 | 204/18723 | 2.99e-06 | 7.93e-05 | 43 |
GO:006157228 | Skin | AK | actin filament bundle organization | 36/1910 | 161/18723 | 4.59e-06 | 1.10e-04 | 36 |
GO:011005328 | Skin | AK | regulation of actin filament organization | 53/1910 | 278/18723 | 5.48e-06 | 1.26e-04 | 53 |
GO:001063420 | Skin | AK | positive regulation of epithelial cell migration | 38/1910 | 176/18723 | 6.10e-06 | 1.39e-04 | 38 |
GO:00518949 | Skin | AK | positive regulation of focal adhesion assembly | 12/1910 | 28/18723 | 7.83e-06 | 1.72e-04 | 12 |
GO:005122226 | Skin | AK | positive regulation of protein transport | 56/1910 | 303/18723 | 7.96e-06 | 1.74e-04 | 56 |
GO:001076924 | Skin | AK | regulation of cell morphogenesis involved in differentiation | 25/1910 | 96/18723 | 8.01e-06 | 1.74e-04 | 25 |
GO:000195419 | Skin | AK | positive regulation of cell-matrix adhesion | 18/1910 | 58/18723 | 1.09e-05 | 2.29e-04 | 18 |
GO:001081127 | Skin | AK | positive regulation of cell-substrate adhesion | 29/1910 | 123/18723 | 1.29e-05 | 2.58e-04 | 29 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ITGB1BP1 | SNV | Missense_Mutation | | c.592N>A | p.Glu198Lys | p.E198K | O14713 | protein_coding | tolerated(0.25) | benign(0.185) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ITGB1BP1 | SNV | Missense_Mutation | | c.83N>G | p.Ser28Cys | p.S28C | O14713 | protein_coding | tolerated(0.12) | probably_damaging(0.996) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ITGB1BP1 | SNV | Missense_Mutation | rs773209764 | c.8G>A | p.Arg3His | p.R3H | O14713 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.991) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
ITGB1BP1 | SNV | Missense_Mutation | | c.83N>A | p.Ser28Tyr | p.S28Y | O14713 | protein_coding | deleterious(0.03) | probably_damaging(0.995) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ITGB1BP1 | SNV | Missense_Mutation | rs376533619 | c.317C>T | p.Pro106Leu | p.P106L | O14713 | protein_coding | tolerated(0.31) | benign(0.007) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ITGB1BP1 | SNV | Missense_Mutation | novel | c.29N>A | p.Ser10Asn | p.S10N | O14713 | protein_coding | tolerated_low_confidence(0.19) | probably_damaging(0.95) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
ITGB1BP1 | SNV | Missense_Mutation | novel | c.122G>A | p.Ser41Asn | p.S41N | O14713 | protein_coding | deleterious(0.03) | probably_damaging(0.988) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
ITGB1BP1 | SNV | Missense_Mutation | novel | c.526N>G | p.Ser176Gly | p.S176G | O14713 | protein_coding | tolerated(0.13) | possibly_damaging(0.59) | TCGA-BK-A6W3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ITGB1BP1 | SNV | Missense_Mutation | novel | c.439G>A | p.Gly147Ser | p.G147S | O14713 | protein_coding | tolerated(0.27) | probably_damaging(0.999) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ITGB1BP1 | SNV | Missense_Mutation | rs771640299 | c.568N>A | p.Ala190Thr | p.A190T | O14713 | protein_coding | tolerated(0.21) | benign(0.207) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |